Annexon(ANNX) - 2025 Q4 - Annual Report

Clinical Development and Trials - Annexon is advancing two late-stage registrational programs: tanruprubart for Guillain-Barré Syndrome (GBS) and vonaprument for geographic atrophy (GA) in dry AMD, targeting significant unmet medical needs[23]. - Tanruprubart has shown that approximately 90% of GBS patients treated improved by week 1, with more than twice as many achieving a normal state of health by week 26 in a Phase 3 trial[24]. - Vonaprument demonstrated a more than 70% reduction in the risk of 15-letter vision loss in the Phase 2 ARCHER trial, addressing the needs of over 8 million patients with GA[27]. - The ongoing Phase 3 ARCHER II trial for vonaprument has enrolled 659 patients, with topline data expected in Q4 2026[28]. - The Phase 1b trial of tanruprubart involved 50 GBS patients, demonstrating that the drug was well tolerated with no serious adverse events reported[59]. - The clinical development of tanruprubart has generated a robust data package, including a successful Phase 3 trial showing faster and more complete functional recovery versus placebo[56]. - The ongoing FORWARD study aims to support a broad label for tanruprubart in GBS, with initial data expected in 2026[76]. - A Phase 2 trial of tanruprubart in Huntington's Disease (HD) showed stabilization of disease progression over nine months, with 28 patients enrolled and safety data from all participants[101]. - In the ALS Phase 2a trial, 13 patients were treated for 12 weeks, showing rapid target engagement and better outcomes for those with higher baseline complement activation[102]. - ANX009, evaluated in a Phase 1b trial for Lupus Nephritis (LN), was well tolerated with sustained C1q inhibition, supporting its potential for chronic dosing[103][105]. Drug Designation and Regulatory Approvals - Tanruprubart has received orphan drug designation from both the FDA and EMA, and a Marketing Authorization Application was filed with the EMA in January 2026[25]. - An MAA for tanruprubart was filed with the EMA in January 2026, and it has received orphan designation from the EMA and Fast Track designation from the FDA[77]. - Orphan Drug designation is granted for drugs intended to treat rare diseases, defined as having a patient population of fewer than 200,000 individuals in the U.S.[155]. - A product with Orphan Drug designation is entitled to seven years of exclusivity upon receiving the first FDA approval for the designated disease[156]. - The FDA may grant priority review designation, which sets a target date for action on a BLA or NDA at six months after acceptance of the application[150]. - The FDA may approve a BLA or NDA with a Risk Evaluation and Mitigation Strategy (REMS) to manage known or potential serious risks associated with a medicine[149]. - The FDA requires substantial time and financial resources for the approval process of new drugs, including compliance with various regulations[134]. - The company must navigate the regulatory landscape, including submitting Investigational New Drug (IND) applications and obtaining approvals for clinical trials[139]. Financial Performance and Projections - The company reported a net loss of approximately $206.7 million for the year ended December 31, 2025, compared to a net loss of $138.2 million for 2024, resulting in an accumulated deficit of $917.4 million as of December 31, 2025[186]. - The company has incurred significant losses since its inception in March 2011, with no products approved for commercial sale and no revenue generated from product candidates[185]. - As of December 31, 2025, the company had capital resources of approximately $238.3 million, expected to fund planned operating expenses into the second half of 2027[188]. - The company anticipates continuing to incur significant losses for the foreseeable future as it develops product candidates and conducts clinical trials[186]. - The company has primarily financed operations through equity securities, with a current offering program allowing for up to $150 million in common stock sales[192]. Research and Development Focus - The company aims to leverage its C1q inhibition platform to develop disease-modifying medicines for neuroinflammatory diseases, enhancing efficacy and safety[40]. - The strategic focus includes expanding the targeted immunotherapy platform and exploring licensing agreements to accelerate development and commercialization[41]. - Annexon has established a strong scientific and clinical rationale for its pipeline, addressing significant unmet medical needs in neuroinflammatory diseases[35]. - Significant resources are required for product development, leading to prioritization among candidates, particularly focusing on tanruprubart in GBS and vonaprument in GA[193]. Market and Competitive Landscape - The company faces intense competition from various sources, including pharmaceutical and biotechnology companies, which may have greater financial resources and established market presence[130]. - There are currently no approved therapies for Guillain-Barré Syndrome (GBS) in the United States, with investigational products in development by other companies[131]. - Two treatments for Geographic Atrophy (GA) received FDA approval in 2023, while there are ongoing clinical trials for additional therapies targeting GA[132]. - Sanofi's Enjaymo was approved for Cold Agglutinin Disease (CAD) in February 2022, and there are ongoing clinical trials for other investigational agents[133]. Operational Challenges - The company currently relies on third-party contract manufacturers for the production of its drug candidates, as it does not own or operate manufacturing facilities[125]. - The company is in discussions with current manufacturers regarding the preparation of a Biologics License Application (BLA) in the near future, with a Marketing Authorization Application (MAA) filed in January 2026[127]. - The company plans to establish long-term supply agreements to ensure continuity in its supply chain and is considering alternative larger scale suppliers for certain portions of its supply chain[128]. - The company faces delays in enrolling patients in clinical trials, which may impact the integrity of subject data and clinical study endpoints[207]. - Increased rates of patient withdrawals from clinical trials due to health conditions have been observed, affecting overall trial outcomes[207]. - The company anticipates potential disruptions in clinical trial operations due to regulatory agency interruptions and supply chain issues[208]. Intellectual Property and Licensing - The patent portfolio includes 19 different patent families filed worldwide, with key patents covering methods of treating neurodegeneration and related conditions[110]. - The company is obligated to pay Stanford up to $675,000 in milestone payments under the exclusive licensing agreement, along with royalties on worldwide net sales[115]. - The company may face challenges in obtaining and maintaining intellectual property rights, which could materially impact its business[121]. Future Risks and Uncertainties - The company faces risks related to the successful development and regulatory approval of product candidates, which are currently in early clinical stages[200]. - Public health crises, such as the COVID-19 pandemic, have previously disrupted clinical trials and may continue to adversely affect business operations[205]. - The variability in quarterly and annual results makes future performance difficult to predict, potentially leading to stock price declines if expectations are not met[199]. - The company may need to relinquish rights to technologies or product candidates through collaborations if additional funds are sought[192]. - The company must comply with varying regulatory requirements across jurisdictions, which could complicate the approval process[215]. - There is a risk that product candidates may not be accepted as safe and effective by the medical community or third-party payors, affecting marketability[212].